Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines
Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in refer...
Sparad:
| Huvudupphov: | , , , , |
|---|---|
| Materialtyp: | Online |
| Språk: | engelska |
| Utgiven: |
Frontiers Media SA
2021
|
| Ämnen: | |
| Länkar: | 22904 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|
| _version_ | 1869526646732619776 |
|---|---|
| author | Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama |
| author_browse | Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Kazuhito Fujiyama Rosella Franconi |
| author_facet | Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama |
| author_sort | Domenico De Martinis |
| collection | Directory of Open Access Books |
| description | Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries. |
| format | Online |
| id | doab-20.500.12854ir-46423 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-464232024-04-11T15:10:48Z Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama TP248.13-248.65 TA1-2040 QK1-989 Q1-390 plant molecular farming Metabolic Engineering transient expression Genetic Engineering recombinant protein biopharmaceuticals Plant factory Biobetter thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries. 2021-02-11T12:35:30Z 2021-02-11T12:35:30Z 2017-07-06 13:27:36 2017 book 22904 16648714 9782889450510 https://directory.doabooks.org/handle/20.500.12854/46423 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Engineering_the_Plant_Factory_for_the_Production_of_Biologics_and_Small-Molecule_Medicines/1180#nogo http://journal.frontiersin.org/researchtopic/3853/engineering-the-plant-factory-for-the-production-of-biologics-and-small-molecule-medicines Frontiers Media SA 10.3389/978-2-88945-051-0 10.3389/978-2-88945-051-0 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889450510 377 open access |
| spellingShingle | TP248.13-248.65 TA1-2040 QK1-989 Q1-390 plant molecular farming Metabolic Engineering transient expression Genetic Engineering recombinant protein biopharmaceuticals Plant factory Biobetter thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title | Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title_full | Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title_fullStr | Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title_full_unstemmed | Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title_short | Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
| title_sort | engineering the plant factory for the production of biologics and small molecule medicines |
| topic | TP248.13-248.65 TA1-2040 QK1-989 Q1-390 plant molecular farming Metabolic Engineering transient expression Genetic Engineering recombinant protein biopharmaceuticals Plant factory Biobetter thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology |
| topic_facet | TP248.13-248.65 TA1-2040 QK1-989 Q1-390 plant molecular farming Metabolic Engineering transient expression Genetic Engineering recombinant protein biopharmaceuticals Plant factory Biobetter thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology |
| url | 22904 |
| work_keys_str_mv | AT domenicodemartinis engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT edwardprybicki engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT eugeniobenvenuto engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT rosellafranconi engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT kazuhitofujiyama engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines |